UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The Lancet (British edition), ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Diabetes. Impaired glucose tolerance | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 04/2020, Volume 43, Issue 4, pp. 921 - 924
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | History, 21st Century | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Diabetes Mellitus, Type 2 - epidemiology | Heart Failure - prevention & control | Practice Patterns, Physicians' - statistics & numerical data | Adult | Female | Immunoglobulin Fc Fragments - therapeutic use | Diabetic Angiopathies - prevention & control | Glucagon-Like Peptides - analogs & derivatives | Heart Failure - epidemiology | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Patient Preference - statistics & numerical data | Hypoglycemic Agents - pharmacology | Practice Patterns, Physicians' - trends | Liraglutide - therapeutic use | Diabetic Angiopathies - epidemiology | Aged | Glucagon-Like Peptides - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Type 2 diabetes | Hypoglycemic agents | Research | Diabetes | Drug therapy | Patient outcomes | Myocardial infarction | Cerebral infarction | Receptors | Stroke | Inhibitors | Glucagon | Initiators | Agonists | Research design | Preferences | Heart diseases | Glucagon-like peptide 1 | Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 10/2009, Volume 32, Issue 10, pp. 1880 - 1886
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Public health. Hygiene-occupational medicine | Public health. Hygiene | Diabetes. Impaired glucose tolerance | Miscellaneous | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Metabolic diseases | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Double-Blind Method | Drug Administration Schedule | Glucagon-Like Peptide 1 - administration & dosage | Glucagon-Like Peptide 1 - analogs & derivatives | Placebo Effect | Humans | Treatment Outcome | Multicenter Studies as Topic | Glucagon-Like Peptide-1 Receptor | Hypoglycemic Agents - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Exercise | Dosage and administration | Metformin | Research | Drug therapy | Health aspects | Studies | Clinical trials | Early intervention | Data analysis | Diabetes | Index Medicus | Original Research
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 10/2014, Volume 124, Issue 10, pp. 4473 - 4488
Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Vagus Nerve - metabolism | Glucagon-Like Peptide 1 - analogs & derivatives | Glucagon-Like Peptide 1 - pharmacology | Body Weight - drug effects | Electrophysiology | Rats | Receptors, Glucagon - metabolism | Male | Mice, Transgenic | Weight Loss - drug effects | Rats, Sprague-Dawley | Nerve Tissue Proteins - metabolism | Pro-Opiomelanocortin - metabolism | Animals | Hypothalamus - metabolism | Glucagon-Like Peptide-1 Receptor | Arcuate Nucleus of Hypothalamus - drug effects | Paraventricular Hypothalamic Nucleus - metabolism | Mice | Neurons - metabolism | Liraglutide | Disease Models, Animal | Neural circuitry | Medical examination | Patient outcomes | Weight loss | Physiological aspects | Hypothalamus | Observations | Obesity | Weight control | Peptides | Rodents | Software | Physiology | Food | Index Medicus | Abridged Index Medicus
Journal Article
Neuropharmacology, ISSN 0028-3908, 07/2018, Volume 136, Issue Pt B, pp. 251 - 259
Inflammation | GLP-1 | Neurodegeneration | Insulin | Growth factors | GIP | Pharmacology & Pharmacy | Neurosciences | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Neuroprotective Agents - therapeutic use | Glucagon-Like Peptide-1 Receptor - metabolism | Animals | Neuroprotective Agents - pharmacology | Humans | Alzheimer Disease - metabolism | Alzheimer Disease - drug therapy | Parkinson Disease - drug therapy | Parkinson Disease - metabolism | Receptors, Gastrointestinal Hormone - metabolism | Receptors, Gastrointestinal Hormone - agonists | Glucagon-Like Peptide-1 Receptor - agonists | Models | Neurons | Alzheimer's disease | Analysis | Risk factors | Index Medicus
Journal Article
Drugs (New York, N.Y.), ISSN 0012-6667, 4/2017, Volume 77, Issue 5, pp. 493 - 503
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Brain - drug effects | Brain - metabolism | Glucagon-Like Peptide-1 Receptor - metabolism | Animals | Hypoglycemic Agents - administration & dosage | Adipocytes - metabolism | Humans | Adipocytes - drug effects | Diabetes Mellitus, Type 2 - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Brain | Transcription | Peptides | Glucagon | Circuits | Arcuate nucleus | Parkinsons disease | Homeostasis | Clinical trials | Body weight loss | Hormones | Adipocytes | Hypothalamus | Glucose | Nuclei | Rodents | Hepatology | Nutrients | Physiology | Glucagon-like peptide 1 | Food | Neuropeptide Y | Obesity | Medical research | Diabetes mellitus | Weight loss | Energy expenditure | Metabolism | Insulin | Microglia | Energy balance | Neurotransmitters | Weight control | Gliosis | Amphetamine | Diet | Food intake | Neural networks | Leptin | Genesis | Cocaine- and amphetamine-regulated transcript protein | Cocaine | Diabetes
Journal Article
Journal of internal medicine, ISSN 0954-6820, 07/2019, Volume 286, Issue 1, pp. 16 - 31
anti‐diabetic drugs | heart failure | SGLT‐2 inhibitors | CV disease | GLP‐1 receptor agonists | diabetes | SGLT-2 inhibitors | GLP-1 receptor agonists | anti-diabetic drugs | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Diabetic Cardiomyopathies - prevention & control | Diabetic Angiopathies - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Diabetes Mellitus, Type 2 - complications | Glucagon-Like Peptide-1 Receptor - agonists | Type 2 diabetes | Cardiovascular diseases | Hypoglycemic agents | Glucagon | Complications | Diabetes mellitus | Health risks | Clinical trials | Pharmacology | Glucose | Inhibitors | Sodium | Arteriosclerosis | Atherosclerosis | Agonists | Diabetes | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus
Journal Article